Evonik is a leading global manufacturer of DL-methionine, an essential amino acid which is used in modern feed formulation, enabling the company to play a pivotal role in addressing sustainable animal protein supply, food safety and animal welfare.
All three of Evonik's world-scale MetAMINO® plants operate along cost leading, best-in-class technology lines, and offer opportunities for further expansion. They are also ready for cost efficient modular debottlenecking in the future.
Following this strategy, Evonik is to close the smallest of its MetAMINO® plants with a capacity of 65,000 tons per year, located in Wesseling, Germany, by the end of the first quarter, 2021.
In addition, Evonik will invest about €25 million into upgrading its world-scale plant for methionine intermediates in Wesseling to safeguard long-term supply to the Antwerp site and to strengthen its European MetAMINO®-Verbund.
This will lead to a better cost position, through improved utilisation of capacity, with economies of scale and an enhanced ability to adapt to any market condition.
Dr Emmanuel Auer, head of Animal Nutrition business line at Evonik, said, 'The methionine business is important for Evonik, now and in the future. We will adapt to market challenges and prepare our asset set-up for highest efficiency and further optimised cost structures. We have engaged in continuous efficiency measures and programs over the past few years. As part of structural asset optimisation, the time felt right to close the smallest methionine asset.'
In 2014, Evonik opened its methionine production facility in Singapore. In 2019 the company doubled the nameplate capacity at the site.
Today Singapore is the largest DL-methionine production complex in the world with a nameplate capacity of 300,000 tons per year MetAMINO®; a new industry standard for efficient, safe and sustainable operation.
Alongside Singapore, Evonik operates world-scale facilities in Mobile, Alabama, USA; and in Antwerp, Belgium. Evonik has been producing MetAMINO® in Wesseling since 1967.
Visit the Evonik website, HERE.
All three of Evonik's world-scale MetAMINO® plants operate along cost leading, best-in-class technology lines, and offer opportunities for further expansion. They are also ready for cost efficient modular debottlenecking in the future.
Following this strategy, Evonik is to close the smallest of its MetAMINO® plants with a capacity of 65,000 tons per year, located in Wesseling, Germany, by the end of the first quarter, 2021.
In addition, Evonik will invest about €25 million into upgrading its world-scale plant for methionine intermediates in Wesseling to safeguard long-term supply to the Antwerp site and to strengthen its European MetAMINO®-Verbund.
This will lead to a better cost position, through improved utilisation of capacity, with economies of scale and an enhanced ability to adapt to any market condition.
Dr Emmanuel Auer, head of Animal Nutrition business line at Evonik, said, 'The methionine business is important for Evonik, now and in the future. We will adapt to market challenges and prepare our asset set-up for highest efficiency and further optimised cost structures. We have engaged in continuous efficiency measures and programs over the past few years. As part of structural asset optimisation, the time felt right to close the smallest methionine asset.'
In 2014, Evonik opened its methionine production facility in Singapore. In 2019 the company doubled the nameplate capacity at the site.
Today Singapore is the largest DL-methionine production complex in the world with a nameplate capacity of 300,000 tons per year MetAMINO®; a new industry standard for efficient, safe and sustainable operation.
Alongside Singapore, Evonik operates world-scale facilities in Mobile, Alabama, USA; and in Antwerp, Belgium. Evonik has been producing MetAMINO® in Wesseling since 1967.
Visit the Evonik website, HERE.
The Global Miller
This blog is maintained by The Global Miller staff and is supported by the magazine Milling and Grain
which is published by Perendale Publishers Limited.
No comments:
Post a Comment